Last reviewed · How we verify
Metformin + Rosuvastatin
This combination reduces blood glucose through metformin's inhibition of hepatic glucose production and increases insulin sensitivity, while rosuvastatin lowers cholesterol by inhibiting HMG-CoA reductase.
This combination reduces blood glucose through metformin's inhibition of hepatic glucose production and increases insulin sensitivity, while rosuvastatin lowers cholesterol by inhibiting HMG-CoA reductase. Used for Type 2 diabetes mellitus with dyslipidemia, Cardiovascular risk reduction in patients with diabetes and elevated cholesterol.
At a glance
| Generic name | Metformin + Rosuvastatin |
|---|---|
| Sponsor | Jeil Pharmaceutical Co., Ltd. |
| Drug class | Antidiabetic agent + HMG-CoA reductase inhibitor (statin) |
| Target | Metformin: AMP-activated protein kinase (AMPK) pathway; Rosuvastatin: HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, primarily used in type 2 diabetes. Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and cardiovascular risk. The combination addresses both glycemic control and lipid management in patients with concurrent diabetes and dyslipidemia.
Approved indications
- Type 2 diabetes mellitus with dyslipidemia
- Cardiovascular risk reduction in patients with diabetes and elevated cholesterol
Common side effects
- Gastrointestinal disturbance (metformin)
- Muscle pain or myalgia (rosuvastatin)
- Elevated liver enzymes
- Headache
- Lactic acidosis (metformin, rare)
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together (PHASE1)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016) (PHASE1)
- A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin + Rosuvastatin CI brief — competitive landscape report
- Metformin + Rosuvastatin updates RSS · CI watch RSS
- Jeil Pharmaceutical Co., Ltd. portfolio CI